Effects of Fibroid Size and Hyaluronan-Enriched Transfer Medium on Clinical Pregnancy and Live Birth: A Retrospective Study
Zercan Kalı, Emrah Zayman, Nihal Mavral · 2026
Read Effects of Fibroid Size and Hyaluronan-Enriched Transfer Medium on Clinical Pregnancy and Live Birth: A Retrospective Study by Zercan Kalı, Emrah Zayman, Nihal Mavral (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13607527.txt.
Introduction
Zercan Kali, Emrah Zayman, and Nihal Mavral look back at fertility treatment records in a 2026 study of women with womb fibroids. Fibroids that sit in the womb wall without bending its cavity still lower the odds in assisted reproduction. A transfer medium enriched with hyaluronan, sold as EmbryoGlue, is meant to help an embryo settle. Whether it offsets the fibroid effect, and whether fibroid size changes the answer, was unexplored.
The single-center study covered five hundred fifteen women aged twenty to thirty-seven, each with the relevant fibroid types and a frozen single embryo transfer between 2021 and 2025. About half received the enriched medium and the rest the standard one. The team compares clinical pregnancy and live birth between the groups, split by fibroid size. The results guide a cheap add-on choice in a common hard case.
Catalog record
| CREATOR | Zercan Kalı, Emrah Zayman, Nihal Mavral |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Effects of Fibroid Size and Hyaluronan-Enriched Transfer Medium on Clinical Pregnancy and Live Birth: A Retrospective Study Authors: Zercan Kalı, Emrah Zayman, Nihal Mavral Published: 2026 ABSTRACT Objective: Non-cavity-distorting intramural fibroids have been linked to poorer reproductive outcomes in assisted reproduction, yet strategies to counteract this effect remain underexplored. This study examined whether a hyaluronan-enriched transfer medium (EmbryoGlue®) is associated with clinical pregnancy and live birth in women with such fibroids undergoing frozen-thawed single blastocyst transfer, and whether any such association depends on fibroid size. Methods: We conducted a single-center retrospective cohort analysis of 515 women, aged 20–37 years, carrying the International Federation of Gynecology and Obstetrics (FIGO) type 3–5 non-cavity-distorting intramural fibroids, who underwent frozen-thawed single blastocyst transfer between January 2021 and December 2025. Of these, 232 received a hyaluronan-enriched transfer medium and 283 received a standard medium. Clinical pregnancy served as the primary endpoint; positive pregnancy test, live birth, and early pregnancy loss were secondary endpoints. Multivariable logistic regression was used to identify independent predictors of clinical pregnancy and live birth and to test for an interaction between EmbryoGlue use and fibroid size. Results: Women who received EmbryoGlue had higher rates of positive pregnancy test (50.0% vs. 32.9%; p < 0.001), clinical pregnancy (40.5% vs. 26.9%; p = 0.001), and live birth (30.2% vs. 19.1%; p = 0.003) than those in the control group. After adjustment, and taking a fibroid size of 3 cm as the reference point, EmbryoGlue use remained associated with greater odds of clinical pregnancy (adjusted odds ratio [aOR] 2.05, 95% CI 1.20–3.50; p = 0.008). A significant interaction between EmbryoGlue use and fibroid size emerged for both clinical pregnancy (aOR 1.74, 95% CI 1.13–2.68; p = 0.011) and live birth (aOR 1.68, 95% CI 1.06–2.67; p = 0.028): the association between EmbryoGlue and reproductive outcomes was not uniform but depended on fibroid size, with the widest gap between groups seen among women with fibroids exceeding 4 cm. Conclusions: Among women with non-cavity-distorting intramural fibroids undergoing frozen-thawed single blastocyst transfer, EmbryoGlue use was linked to more favorable reproductive outcomes overall, an association that varied by fibroid size and was most pronounced above 4 cm. These findings warrant confirmation through prospective randomized trials before influencing clinical practice. 1. Introduction Whether non-cavity-distorting intramural fibroids compromise the success of assisted reproductive technology (ART) remains a matter of ongoing debate, although several recent meta-analyses point toward a detrimental influence on clinical pregnancy and live birth rates [1,2,3]. In a pooled analysis of 5029 women, Rikhraj and colleagues reported that live birth was roughly 44% less likely in the presence of these fibroids [1]. Sunkara and colleagues similarly documented worse outcomes even when the uterine cavity itself was not distorted [2], while Erden and colleagues described reduced clinical pregnancy and live birth rates for fibroids up to 6 cm in size [3]. Most of the underlying evidence, however, comes from retrospective cohorts, leaving open questions about how fibroid size and specific treatment approaches interact to shape in vitro fertilization (IVF) success. Intramural fibroids are among the most common uterine pathologies encountered in women of reproductive age, and their management in the context of infertility remains a persistent clinical dilemma. Surgical removal carries its own risks, including bleeding, adhesion formation, and a potential reduction in ovarian reserve, while a conservative approach leaves the fibroid’s possible adverse influence on implantation unaddressed [1,2,3]. This tension has motivated growing interest in non-surgical strategies that might mitigate the impact of fibroids on IVF outcomes without exposing patients to operative risk. Successful implantation depends on a combination of factors, including embryo quality, the receptivity of the endometrium, and the molecular dialogue that takes place between the two [4,5]. Various adjuncts have been explored to optimize this environment, ranging from modifications of the transfer medium itself to endometrial injection of embryo culture supernatant [6]. Among these, supplementing the transfer medium with hyaluronan—a glycosaminoglycan found naturally in cervical mucus, follicular fluid, and endometrial tissue, and believed to promote implantation through CD44-receptor interactions on both the embryo and the endometrium [5,7]—has received particular attention in the literature. Several clinical trials and meta-analyses evaluating hyaluronan-enriched media report modest gains in clinical pregnancy and live birth rates in certain patient groups, lending support to the broader hypothesis that such media can reinforce embryo–endometrium interaction [7]. EmbryoGlue®, a transfer medium enriched with hyaluronan, is designed to facilitate closer contact and adhesion between the embryo and the endometrial surface. Evidence on how well it performs specifically in women with intramural fibroids is scarce, and no study to date has adequately examined whether its performance depends on fibroid size. Because non-cavity-distorting fibroids are thought to impair endometrial receptivity and implantation through mechanical or functional pathways [1,2,3], we reasoned that a hyaluronan-enriched medium might offer a proportionally greater benefit in this specific population, and that this benefit might become more evident as fibroid size increases. Accordingly, the present study set out to examine the relationship between EmbryoGlue use and clinical pregnancy and live birth among women with non-cavity-distorting intramural fibroids undergoing frozen-thawed single blastocyst transfer, and to test whether this relationship is modified by fibroid size (EmbryoGlue × fibroid-size interaction). 2. Materials and Methods 2.1. Study Design This retrospective single-center cohort study was based on a review of the clinical records of women who had undergone IVF/intracytoplasmic sperm injection (ICSI) treatment at the Private Malatya Gözde Academy IVF Center, Türkiye, between January 2021 and December 2025. A total of 515 women with non-cavity-distorting intramural fibroids who met the study eligibility criteria were included. Clinical, embryological, and reproductive outcome data were retrieved from the institutional electronic medical records. Throughout the study period, all ovarian stimulation protocols, embryo culture conditions, embryo grading procedures, vitrification–warming protocols, and frozen-thawed single blastocyst transfer procedures were performed according to standardized institutional protocols. The study was reported in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement. 2.2. Ethical Approval The study was conducted in accordance with the principles of the Declaration of Helsinki. The study protocol was submitted to the Ethics Committee of Malatya Turgut Özal University on 1 November 2025 (Application No. 2025/415) and was approved by the Ethics Committee on 16 February 2026. Due to the retrospective nature of the study and the use of anonymized clinical data, the requirement for written informed consent was waived by the Ethics Committee. 2.3. Patient Selection Patients with non-cavity-distorting intramural fibroids who underwent frozen-thawed single blastocyst transfer were included in the study. Patients were divided into two groups according to the transfer medium used: the EmbryoGlue group and the standard transfer medium (control) group. Inclusion criteria:Age between 20 and 37 years;Presence of a non-cavity-distorting intramural fibroid confirmed by Ttransvaginal ultrasonography (TVUS);Frozen-thawed single blastocyst transfer performed on day 5 or 6;Availability of follow-up data on clinical pregnancy and live birth outcomes. Age between 20 and 37 years; Age between 20 and 37 years; Presence of a non-cavity-distorting intramural fibroid confirmed by Ttransvaginal ultrasonography (TVUS); Presence of a non-cavity-distorting intramural fibroid confirmed by Ttransvaginal ultrasonography (TVUS); Frozen-thawed single blastocyst transfer performed on day 5 or 6; Frozen-thawed single blastocyst transfer performed on day 5 or 6; Availability of follow-up data on clinical pregnancy and live birth outcomes. Availability of follow-up